| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $2,296 | 1 | 25 |
Sells | $22,327 | 3 | 75 |
| GILEAD SCIENCES, INC. | 10 percent owner | 1 | $2,296 | 0 | $0 | $2,296 |
| White Nicole S | Chief Manufacturing Officer | 0 | $0 | 1 | $5,258 | $-5,258 |
| Bjorkquist Jeanette M | PFO and PAO | 0 | $0 | 2 | $17,070 | $-17,070 |
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Over the last 12 months, insiders at Assembly Biosciences, Inc. have bought $2,296 and sold $22,327 worth of Assembly Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Assembly Biosciences, Inc. have bought $7.19M and sold $77,888 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $2,296.
The last purchase of 2,295,920 shares for transaction amount of $2,296 was made by GILEAD SCIENCES, INC. (10 percent owner) on 2025‑08‑08.
| 2026-03-30 | Sale | White Nicole S | Chief Manufacturing Officer | 197 0.0012% | $26.69 | $5,258 | +6.23% | |
| 2026-03-30 | Sale | Bjorkquist Jeanette M | PFO and PAO | 312 0.002% | $26.65 | $8,315 | +6.23% | |
| 2026-03-30 | Sale | Bjorkquist Jeanette M | PFO and PAO | 328 0.0021% | $26.69 | $8,755 | +6.23% | |
| 2025-08-08 | GILEAD SCIENCES, INC. | 10 percent owner | 2.3M 0.0012% | $0.00 | $2,296 | +18.52% | ||
| 2025-03-31 | Sale | McHutchison John G | director | 757 0.0104% | $9.85 | $7,455 | +168.41% | |
| 2025-03-31 | Sale | Okazaki Jason A | CEO and President | 355 0.0049% | $9.85 | $3,496 | +168.41% | |
| 2025-03-31 | Sale | White Nicole S | Chief Manufacturing Officer | 197 0.0027% | $9.85 | $1,940 | +168.41% | |
| 2025-03-31 | Sale | Bjorkquist Jeanette M | Principal Accounting Officer | 180 0.0025% | $9.85 | $1,773 | +168.41% | |
| 2024-12-30 | Houghton Michael | director | 3,202 0.0519% | $15.61 | $49,998 | +12.35% | ||
| 2024-12-19 | GILEAD SCIENCES, INC. | 10 percent owner | 940,499 20.3736% | $21.37 | $20.1M | +9.80% | ||
| 2024-11-25 | Schornstein Alexander | 10 percent owner | 7,976 0.126% | $14.91 | $118,890 | +13.37% | ||
| 2024-11-22 | Schornstein Alexander | 10 percent owner | 17,024 0.2729% | $14.87 | $253,104 | +11.04% | ||
| 2024-11-18 | Sale | White Nicole S | Chief Manufacturing Officer | 40 0.0006% | $16.29 | $652 | +2.75% | |
| 2024-10-08 | Schornstein Alexander | 10 percent owner | 10,000 0.1478% | $14.58 | $145,800 | +11.37% | ||
| 2024-10-03 | Sale | Okazaki Jason A | CEO and President | 197 0.003% | $14.81 | $2,918 | +9.02% | |
| 2024-10-03 | Sale | White Nicole S | Chief Manufacturing Officer | 157 0.0024% | $14.81 | $2,325 | +9.02% | |
| 2024-08-02 | Sale | Okazaki Jason A | CEO and President | 981 0.0158% | $14.23 | $13,962 | +5.25% | |
| 2024-08-02 | Sale | White Nicole S | Chief Manufacturing Officer | 785 0.0127% | $14.23 | $11,173 | +5.25% | |
| 2024-07-05 | Schornstein Alexander | 10 percent owner | 4,438 0.063% | $12.52 | $55,564 | +12.04% | ||
| 2024-07-03 | Schornstein Alexander | 10 percent owner | 4,562 0.0636% | $12.29 | $56,067 | +21.77% |
| GILEAD SCIENCES, INC. | 10 percent owner | 4505391 28.3484% | $101.51M | 3 | 0 | +3.4% |
| White Nicole S | Chief Manufacturing Officer | 37477 0.2358% | $844,356.81 | 0 | 10 | |
| Bjorkquist Jeanette M | PFO and PAO | 11089 0.0698% | $249,835.17 | 0 | 8 | |
| Schornstein Alexander | 10 percent owner | 728113 4.5814% | $16.4M | 9 | 0 | +36.18% |
| Small Derek A | CEO and President | 669291 4.2113% | $15.08M | 3 | 0 | <0.0001% |
| Lopatin Uri A | Chief Med. Off., VP Res. Dev. | 613611 3.8609% | $13.82M | 0 | 2 | |
| Delaney William E IV | Chief Scientific Officer | 150853 0.9492% | $3.4M | 0 | 8 | |
| Colonno Richard James | EVP & CSO, Virology Ops | 137009 0.8621% | $3.09M | 0 | 2 | |
| Samar Michael P. | Chief Financial Officer | 77228 0.4859% | $1.74M | 0 | 2 | |
| ELLISON RUSSELL H | Chief Executive Officer | 58000 0.3649% | $1.31M | 6 | 0 | +59.75% |
| BARRETT DAVID JONATHAN | Chief Financial Officer | 46980 0.2956% | $1.06M | 3 | 0 | +86.04% |
| Stamm Luisa M | Chief Medical Officer | 40315 0.2537% | $908,296.95 | 0 | 2 | |
| Papkoff Jacqueline Sybil | SVP-CSO Microbiome | 37364 0.2351% | $841,810.92 | 0 | 3 | |
| RINGO WILLIAM R | director | 19465 0.1225% | $438,546.45 | 0 | 11 | |
| McHutchison John G | director | 18347 0.1154% | $413,357.91 | 0 | 9 | |
| Okazaki Jason A | CEO and President | 14757 0.0929% | $332,475.21 | 0 | 14 | |
| Houghton Michael | director | 3202 0.0201% | $72,141.06 | 1 | 0 | +12.35% |
$27,082,337 | 104 | 6.73% | $371.69M | |
$6,125,624 | 95 | -6.06% | $338.04M | |
$63,049,419 | 31 | 2.87% | $329.81M | |
Assembly Biosciences, Inc. (ASMB) | $22,017,898 | 24 | 39.19% | $358.07M |
$112,238,340 | 19 | 39.16% | $432.44M | |
$2,516,932 | 19 | -15.78% | $413M | |
$15,467,825 | 18 | 4.98% | $366.83M | |
$65,355,913 | 13 | -3.42% | $398.68M | |
$101,822,203 | 13 | 84.03% | $321.58M | |
$176,565 | 8 | -2.61% | $355.76M | |
$17,675,244 | 7 | 92.20% | $368M | |
$556,839 | 5 | 13.42% | $320.54M | |
$12,035,408 | 5 | -37.54% | $395.88M | |
$51,688 | 4 | -26.18% | $365.96M | |
$58,352 | 4 | -43.78% | $395.67M | |
$10,104,842 | 3 | 5.45% | $329.79M | |
$184,294 | 3 | -10.64% | $348.92M | |
$20,020,000 | 1 | -75.24% | $344.64M | |
$3,850,000 | 1 | -51.32% | $324.66M |
| Increased Positions | 47 | +88.68% | 2M | +17.99% |
| Decreased Positions | 21 | -39.62% | 1M | -8.32% |
| New Positions | 24 | New | 1M | New |
| Sold Out Positions | 8 | Sold Out | 566,594 | Sold Out |
| Total Postitions | 79 | +49.06% | 14M | +9.66% |
| Gilead Sciences, Inc. | $152,034.00 | 28.16% | 4.51M | +2M | +103.91% | 2025-09-30 |
| Farallon Capital Management Llc | $41,425.00 | 7.67% | 1.23M | +1M | New | 2025-09-30 |
| Ra Capital Management, L.P. | $34,434.00 | 6.38% | 1.02M | +1M | New | 2025-09-30 |
| Commodore Capital Lp | $33,745.00 | 6.25% | 1M | +1M | New | 2025-09-30 |
| Janus Henderson Group Plc | $25,397.00 | 4.7% | 752,626 | +752,626 | New | 2025-09-30 |
| Vanguard Group Inc | $16,944.00 | 3.14% | 502,112 | +248,287 | +97.82% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $15,396.00 | 2.85% | 456,249 | +456,249 | New | 2025-09-30 |
| Blackstone Inc. | $15,111.00 | 2.8% | 447,789 | +447,789 | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $9,989.00 | 1.85% | 296,017 | +296,017 | New | 2025-09-30 |
| Parkman Healthcare Partners Llc | $8,469.00 | 1.57% | 250,981 | +250,981 | New | 2025-09-30 |